001475947 000__ 06390cam\\22006257a\4500
001475947 001__ 1475947
001475947 003__ OCoLC
001475947 005__ 20231003174625.0
001475947 006__ m\\\\\o\\d\\\\\\\\
001475947 007__ cr\cn\nnnunnun
001475947 008__ 230812s2023\\\\sz\\\\\\o\\\\\001\0\eng\d
001475947 019__ $$a1396912246$$a1397683622
001475947 020__ $$a9783031351556
001475947 020__ $$a303135155X
001475947 0247_ $$a10.1007/978-3-031-35155-6$$2doi
001475947 035__ $$aSP(OCoLC)1393308349
001475947 040__ $$aEBLCP$$beng$$cEBLCP$$dGW5XE$$dQGK
001475947 049__ $$aISEA
001475947 050_4 $$aRM666.C266
001475947 08204 $$a615.7/827$$223/eng/20230816
001475947 1001_ $$aRoss, Ivan A.,$$eauthor.
001475947 24510 $$aPlant-based therapeutics.$$nVolume 1 :$$bcannabis sativa /$$cIvan A. Ross.
001475947 24630 $$aCannabis sativa
001475947 260__ $$aCham, Switzerland :$$bSpringer,$$c[2023]
001475947 300__ $$a1 online resource (670 p.)
001475947 336__ $$atext$$btxt$$2rdacontent
001475947 337__ $$acomputer$$bc$$2rdamedia
001475947 338__ $$aonline resource$$bcr$$2rdacarrier
001475947 500__ $$aDescription based upon print version of record.
001475947 500__ $$aIncludes index.
001475947 500__ $$aCannabis on Heart Rate and EEG
001475947 5050_ $$aIntro -- Contents -- Abbreviations -- Chapter 1: The History of Cannabis -- Cannabis sativa L., fam. Cannabinaceae -- Botanical Description -- Origin and Distribution -- Chapter 2: The Bioactive Components of Plants -- Flavonoids -- Proteins and Peptides -- Glycosides -- Alkaloids -- Lignans -- Resins -- Saponins -- References -- Chapter 3: Chemical Constituents of Cannabis -- Chemical Constituents -- References -- Chapter 4: The Bioactive Components of Cannabis -- The Endocannabinoid System -- The Entourage Effect of the Phytochemicals -- Biosynthetic Pathways -- Cannabinoid Receptors
001475947 5058_ $$aEndocannabinoids in the Circulation -- Endocannabinoids and Food -- Endocannabinoids and Body Mass Index -- Endocannabinoid and Circadian Rhythm -- Endocannabinoids and Exercise -- Endocannabinoids and Inflammation -- The Endocannabinoids and Stress -- Endocannabinoids and Chronic SNS or HPA Axis Activation -- Endocannabinoids in Reward, Anxiety, and Cognition -- Cannabinoids and Cognitive Functions -- The Endocannabinoids and Pain -- Terpenes -- Phenols -- Trichomes -- Adverse Effects of Cannabinoids -- References -- Chapter 5: Neurological Effects of Cannabis
001475947 5058_ $$aFactors Affecting the Impact of Cannabis Use on the Brain -- Duration of Abstinence -- Age of Onset of Cannabis Use -- Frequency and Magnitude of Cannabis Use -- Errors in Monitoring Awareness, Reward Processing, and Affective Processing -- Functional MRI Studies on Cannabis -- Endocannabinoid-Mediated LTP in Learning -- The Homosynaptic and Heterosynaptic eCB-Mediated Potentiation -- Memory and Cognitive Impairments -- Cannabis on Attention and Working Memory -- Cannabis and Spatial Working Memory -- Cannabis and Executive Function -- Neuropsychological Functioning in First-Episode Psychosis
001475947 5058_ $$aNeurobiological Alterations During Pregnancy and Breastfeeding -- Cannabis in Adolescence -- Cannabis and Schizophrenia -- Cannabis and Bipolar Disorder -- Cannabis in Alzheimer's and Parkinson's Diseases -- Cannabis and Alcohol Consumption -- Cannabis and Tobacco Coadministration -- Medical vs. Recreational Cannabis Use -- Cannabis Flowers vs. Concentrate -- Acute Administration of Delta-9-THC vs. CBD -- Delta-9-THC vs. Delta-9-Tetrahydrocannabivarin -- Delta-8-THC vs. Delta-9-THC -- Drug Addiction -- Cannabinoids and Pain -- Cannabis and Gender Differences -- Cannabis and HIV
001475947 506__ $$aAccess limited to authorized users.
001475947 520__ $$aBy examining historical applications of the compounds found in plants, this five-volume series serves as a reference for quality assurance, research, product development, and regulatory guidance of the compounds found in plant-based medicines. This work supports the growing consumers' interest in herbal medicine for wellness and health. Plant-Based Therapeutics, Volume 1: Cannabis sativa, the first in the series, covers a unique plant species and provides the framework to integrate its evidence-based scientific discoveries with healthcare therapies. Cannabis has been used in religious ceremonies and medical purposes for thousands of years. Cannabidiol (CBD), the main non-psychoactive component of Cannabis, was isolated in the 1940s, and its structure was established in the 1960s. In 1964 tetrahydrocannabinol (THC), the psychoactive component, was isolated. Cannabis has more than 500 components, of which 104 cannabinoids have been identified. Two of them, THC and CBD, have been the primary components of scientific investigations. They were approved by the FDA for chemotherapy-induced nausea and vomiting in 1985; for appetite stimulation in wasting conditions, such as AIDS, in 1992, and in 2018 for treating two forms of pediatric epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. Beyond the indications for which cannabinoids are FDA-approved, the evidence reveals that cannabinoid receptors are present throughout the body, embedded in cell membranes, and are believed to be more numerous than any other receptor system. When cannabinoid receptors are stimulated, a variety of physiologic processes ensue. Thus, other constituents of Cannabis are extremely promising either as individual compounds or their potential synergistic or entourage effects in the treatment of numerous medical conditions. .
001475947 650_0 $$aCannabis$$xTherapeutic use.
001475947 650_0 $$aMedicinal plants.
001475947 655_0 $$aElectronic books.
001475947 77608 $$iPrint version:$$aRoss, Ivan A.$$tPlant-Based Therapeutics, Volume 1$$dCham : Springer International Publishing AG,c2023$$z9783031351549
001475947 852__ $$bebk
001475947 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-35155-6$$zOnline Access$$91397441.1
001475947 909CO $$ooai:library.usi.edu:1475947$$pGLOBAL_SET
001475947 980__ $$aBIB
001475947 980__ $$aEBOOK
001475947 982__ $$aEbook
001475947 983__ $$aOnline
001475947 994__ $$a92$$bISE